Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

1.

[Medication for ADHD and the risk of cardiovascular mortality].

Langendijk PN, Wilde AA.

Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1713-4. Dutch.

PMID:
16924941
[PubMed - indexed for MEDLINE]
2.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
[PubMed - indexed for MEDLINE]
3.

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC.

Drug Saf. 2009;32(11):1089-96. doi: 10.2165/11317630-000000000-00000.

PMID:
19810780
[PubMed - indexed for MEDLINE]
4.

Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.

Silva RR, Skimming JW, Muniz R.

Clin Pediatr (Phila). 2010 Sep;49(9):840-51. doi: 10.1177/0009922810368289.

PMID:
20693523
[PubMed - indexed for MEDLINE]
5.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.

J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56. doi: 10.1016/j.jaac.2011.11.008. Epub 2011 Dec 20.

PMID:
22265361
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
[PubMed - indexed for MEDLINE]
7.

[Medication for ADHD and the risk of cardiovascular mortality].

Kalverdijk LJ, Buitelaar JK, van der Gaag RJ.

Ned Tijdschr Geneeskd. 2006 Oct 14;150(41):2283-4; author reply 2284. Dutch. No abstract available.

PMID:
17078147
[PubMed - indexed for MEDLINE]
8.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.

J Clin Psychiatry. 2005 Feb;66(2):253-9.

PMID:
15705013
[PubMed - indexed for MEDLINE]
9.

Encouraging news about ADHD drugs and heart risk in adults.

[No authors listed]

Harv Ment Health Lett. 2012 Mar;28(9):7. No abstract available.

PMID:
22474711
[PubMed - indexed for MEDLINE]
10.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
11.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
[PubMed - indexed for MEDLINE]
12.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
[PubMed - indexed for MEDLINE]
13.

Stimulants and sudden death: what is a physician to do?

Wilens TE, Prince JB, Spencer TJ, Biederman J.

Pediatrics. 2006 Sep;118(3):1215-9. Review.

PMID:
16951018
[PubMed - indexed for MEDLINE]
Free Article
14.

Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder.

Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F.

Adv Ther. 2007 Jan-Feb;24(1):182-8.

PMID:
17526476
[PubMed - indexed for MEDLINE]
15.

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

Winterstein AG, Gerhard T, Shuster J, Saidi A.

Pediatrics. 2009 Jul;124(1):e75-80. doi: 10.1542/peds.2008-3138.

PMID:
19564272
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
[PubMed - indexed for MEDLINE]
17.

Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.

Knight M.

Pediatrics. 2007 Jan;119(1):154-5. No abstract available.

PMID:
17200281
[PubMed - indexed for MEDLINE]
Free Article
18.

Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

Samuels JA, Franco K, Wan F, Sorof JM.

Pediatr Nephrol. 2006 Jan;21(1):92-5. Epub 2005 Oct 28.

PMID:
16254730
[PubMed - indexed for MEDLINE]
19.

Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.

Olfson M, Marcus SC, Zhang HF, Wan GJ.

J Manag Care Pharm. 2007 Sep;13(7):570-7.

PMID:
17874863
[PubMed - indexed for MEDLINE]
Free Article
20.

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.

Pediatrics. 2007 Dec;120(6):e1494-501.

PMID:
18055666
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk